Pharma: Expand CMO/CDMO Business at Medreich

Meiji Holdings Co., Ltd. Financial Results for FYE March 2018and New Medium-term Business Plan

	TOP

	Financial Results for FYE March 2018 and New Medium-term Business Plan

	Agenda

	1. Overview of STEP UP 17

	2. The Meiji Group 2026 Vision

	3. The New Medium-term Business Plan Key Strategies Food: Expanding Yogurt, Chocolate, and Nutritional Products Food: Cultivate Future Growth Drivers Pharma: Maximize Product Value in Core Domains and Enhance Presence Pharma: Expand Sales of Generic Drugs and Accelerate Biosimilar Development to Drive Growth Food: Launch High Value-added Products, Invest Intensely in Overseas Business Pharma: Expand CMO/CDMO Business at Medreich Food: Continue Structural Reforms to Improve Productivity Food: Improve Profitability in Milk Business Pharma: Structural Reform and Platform Development to Grow Income from Overseas Agricultural Chemicals and Veterinary Drug Business KPIs - The New Medium-term Business Plan (1) KPIs - The New Medium-term Business Plan (2) Use of Cash Flows

	4. Outlook for the FYE March 2019

	Appendix: Financial data

	Appendix: Topics

	Back cover

Pharma: Expand CMO/CDMO Business at Medreich

Prev. Page

Next Page

Download the PDF

Pharmaceutical segment

• Overseas business: one of the core business in Pharmaceutical segment

• Increase income

• CMO and CDMO business in Medreich drives overseas business

Medreich

• Strengths: low-cost production and suitable quality

• Manufacture products for 50 countries around the world excluding the US

• Business partners are major global corporations: Pfizer, GSK, Novartis

• Needs for CMO, CDMO business expected to grow

• Boost orders from global pharmaceutical companies

• Acquire new customers